Onconova Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.78
- Today's High:
- $0.8
- Open Price:
- $0.78
- 52W Low:
- $0.62
- 52W High:
- $1.49
- Prev. Close:
- $0.78
- Volume:
- 20887
Company Statistics
- Market Cap.:
- $16.37 million
- Book Value:
- 0.901
- Revenue TTM:
- $226000
- Operating Margin TTM:
- -9788.5%
- Gross Profit TTM:
- $226000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -35.21%
- Return on Equity TTM:
- -72.65%
Company Profile
Onconova Therapeutics Inc had its IPO on 2013-07-25 under the ticker symbol ONTX.
The company operates in the Healthcare sector and Biotechnology industry. Onconova Therapeutics Inc has a staff strength of 16 employees.
Stock update
Shares of Onconova Therapeutics Inc opened at $0.78 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.78 - $0.8, and closed at $0.79.
This is a +1.65% increase from the previous day's closing price.
A total volume of 20,887 shares were traded at the close of the day’s session.
In the last one week, shares of Onconova Therapeutics Inc have slipped by -0.89%.
Onconova Therapeutics Inc's Key Ratios
Onconova Therapeutics Inc has a market cap of $16.37 million, indicating a price to book ratio of 0.4735 and a price to sales ratio of 65.4309.
In the last 12-months Onconova Therapeutics Inc’s revenue was $226000 with a gross profit of $226000 and an EBITDA of $-22108000. The EBITDA ratio measures Onconova Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Onconova Therapeutics Inc’s operating margin was -9788.5% while its return on assets stood at -35.21% with a return of equity of -72.65%.
In Q2, Onconova Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Onconova Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Onconova Therapeutics Inc’s profitability.
Onconova Therapeutics Inc stock is trading at a EV to sales ratio of 150.4738 and a EV to EBITDA ratio of 1.5198. Its price to sales ratio in the trailing 12-months stood at 65.4309.
Onconova Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $30.47 million
- Total Liabilities
- $8.67 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Onconova Therapeutics Inc ended 2024 with $30.47 million in total assets and $0 in total liabilities. Its intangible assets were valued at $30.47 million while shareholder equity stood at $18.90 million.
Onconova Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $8.67 million in other current liabilities, 210000.00 in common stock, $-473708000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29.73 million and cash and short-term investments were $29.73 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Onconova Therapeutics Inc’s total current assets stands at $30.45 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $17000.00 compared to accounts payable of $5.07 million and inventory worth $0.
In 2024, Onconova Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Onconova Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.79
- 52-Week High
- $1.49
- 52-Week Low
- $0.62
- Analyst Target Price
- $7.5
Onconova Therapeutics Inc stock is currently trading at $0.79 per share. It touched a 52-week high of $1.49 and a 52-week low of $1.49. Analysts tracking the stock have a 12-month average target price of $7.5.
Its 50-day moving average was $0.95 and 200-day moving average was $0.94 The short ratio stood at 1.46 indicating a short percent outstanding of 0%.
Around 55% of the company’s stock are held by insiders while 680.7% are held by institutions.
Frequently Asked Questions About Onconova Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.